new technologies competing with glp-1 medications 2025 Designing delivery: structural perspectives and formulation approaches for optimized therapy GLP-1 2.0: Where the Next

Excitotoxicity revisited: mitochondria on the verge of a nervous breakdown

This study highlights the growing need for evidence-based conversations between endocrinologists, obstetricians, and primary care physicians to ensure informed, patient-centered decisions

This therapy is commonly considered when: Weight management has been difficult despite lifestyle efforts Blood sugar or metabolic markers require clinical support Appetite regulation is a concern Ongoing provider monitoring is preferred Men receiving care at our Frederick clinic are evaluated individually to ensure GLP-1 therapy aligns with their health profile and treatment goals

alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinsons disease

Nature Materials , 7 (8), 672677